204 related articles for article (PubMed ID: 8060667)
1. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
2. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Hamajima K; Shigematsu T; Yamamato A; Kawamoto S
J Clin Lab Immunol; 1993; 40(3):97-113. PubMed ID: 7877154
[TBL] [Abstract][Full Text] [Related]
3. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
4. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
8. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
11. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
12. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
[TBL] [Abstract][Full Text] [Related]
15. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
17. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
20. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]